FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to medicine, and concerns a synergistic anticancer combination (inhibiting cell proliferation) of aplidine and another drug selected from the group consisting of paclitaxel, cisplatin, arsenic trioxide, 5-fluorouracil, carboplatin, 7-ethyl-10-hydroxycamptothecin, etoposide , melphalan, dexamethasone, Bortezomib, lenalidomide and rituximab, wherein the cancer is selected from lung cancer, breast cancer, colon cancer, prostate cancer, melanoma, multiple myeloma and lymphoma. The group of inventions also concerns the use of this combination to inhibit cancer cell proliferation, a method of treating cancer comprising administering said combination to the patient.
EFFECT: group of inventions provides a synergistic effect on cancer.
68 cl, 10 ex, 85 dwg, 21 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| NEW SYNERGETIC EFFECTS | 2009 |
|
RU2471499C2 |
| METHOD OF TREATING MULTIPLE MYELOMA | 2009 |
|
RU2519750C2 |
| PHARMACEUTICAL COMBINATIONS OF HISTONE DEACETYLASE INHIBITOR AND PROTEASOME INHIBITOR OR IMMUNOMODULATORY DRUG FOR TREATING BLOOD CANCER | 2017 |
|
RU2721409C1 |
| COMBINATION THERAPY WITH ANTITUMOR ALKALOID | 2011 |
|
RU2743643C2 |
| COMBINATION THERAPY WITH ANTICANCER ALKALOID | 2018 |
|
RU2767664C2 |
| COMBINATION THERAPY WITH ANTITUMOR ALKALOID | 2018 |
|
RU2757373C2 |
| COMBINATION THERAPY WITH AN ANTITUMOR ALKALOID | 2011 |
|
RU2605335C2 |
| ANTI-CD38 ANTIBODY AND LENALTDOMID OR BORTEZOMIB FOR TREATING MULTIPLE MYELOMA AND NHL | 2011 |
|
RU2595839C2 |
| APLIDINE FOR TREATMENT OF MYELOMA | 2004 |
|
RU2335294C2 |
| COMPOSITIONS AND METHODS FOR TREATING DISEASE | 2007 |
|
RU2482877C2 |
